Hubei Jumpcan Pharmaceutical Co Ltd - Asset Resilience Ratio
Hubei Jumpcan Pharmaceutical Co Ltd (600566) has an Asset Resilience Ratio of 47.16% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital to net assets of Hubei Jumpcan Pharmaceutical Co Ltd to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2002–2025)
This chart shows how Hubei Jumpcan Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Hubei Jumpcan Pharmaceutical Co Ltd assets under control.
Liquid Assets Composition Over Time
This chart breaks down Hubei Jumpcan Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore 600566 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥8.02 Billion | 47.16% |
| Total Liquid Assets | CN¥8.02 Billion | 47.16% |
Asset Resilience Insights
- Very High Liquidity: Hubei Jumpcan Pharmaceutical Co Ltd maintains exceptional liquid asset reserves at 47.16% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Hubei Jumpcan Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Hubei Jumpcan Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Torrent Pharmaceuticals Limited
NSE:TORNTPHARM |
Drug Manufacturers - Specialty & Generic | 2.79% |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Beijing Tongrentang Co Ltd
SHG:600085 |
Drug Manufacturers - Specialty & Generic | 2.51% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423 |
Drug Manufacturers - Specialty & Generic | 20.44% |
|
Harbin Pharmaceutical Group Co Ltd
SHG:600664 |
Drug Manufacturers - Specialty & Generic | 0.97% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
Annual Asset Resilience Ratio for Hubei Jumpcan Pharmaceutical Co Ltd (2002–2025)
The table below shows the annual Asset Resilience Ratio data for Hubei Jumpcan Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 35.40% | CN¥6.27 Billion ≈ $916.85 Million |
CN¥17.70 Billion ≈ $2.59 Billion |
+7.44pp |
| 2024-12-31 | 27.96% | CN¥5.16 Billion ≈ $755.21 Million |
CN¥18.46 Billion ≈ $2.70 Billion |
+10.44pp |
| 2023-12-31 | 17.52% | CN¥3.18 Billion ≈ $465.08 Million |
CN¥18.14 Billion ≈ $2.65 Billion |
-2.81pp |
| 2022-12-31 | 20.32% | CN¥3.04 Billion ≈ $445.51 Million |
CN¥14.98 Billion ≈ $2.19 Billion |
+6.51pp |
| 2021-12-31 | 13.81% | CN¥1.68 Billion ≈ $245.11 Million |
CN¥12.13 Billion ≈ $1.78 Billion |
+1.84pp |
| 2020-12-31 | 11.96% | CN¥1.26 Billion ≈ $184.08 Million |
CN¥10.52 Billion ≈ $1.54 Billion |
+9.77pp |
| 2019-12-31 | 2.19% | CN¥190.00 Million ≈ $27.80 Million |
CN¥8.66 Billion ≈ $1.27 Billion |
-1.50pp |
| 2018-12-31 | 3.69% | CN¥288.00 Million ≈ $42.14 Million |
CN¥7.80 Billion ≈ $1.14 Billion |
-6.39pp |
| 2017-12-31 | 10.09% | CN¥672.00 Million ≈ $98.33 Million |
CN¥6.66 Billion ≈ $974.94 Million |
+5.88pp |
| 2016-12-31 | 4.21% | CN¥210.00 Million ≈ $30.73 Million |
CN¥4.99 Billion ≈ $729.84 Million |
+0.58pp |
| 2015-12-31 | 3.63% | CN¥130.00 Million ≈ $19.02 Million |
CN¥3.59 Billion ≈ $524.66 Million |
-4.71pp |
| 2014-12-31 | 8.34% | CN¥280.00 Million ≈ $40.97 Million |
CN¥3.36 Billion ≈ $491.34 Million |
+8.29pp |
| 2006-12-31 | 0.05% | CN¥400.00K ≈ $58.53K |
CN¥786.51 Million ≈ $115.09 Million |
-5.83pp |
| 2003-12-31 | 5.88% | CN¥38.22 Million ≈ $5.59 Million |
CN¥650.39 Million ≈ $95.17 Million |
-1.38pp |
| 2002-12-31 | 7.26% | CN¥44.08 Million ≈ $6.45 Million |
CN¥607.22 Million ≈ $88.85 Million |
-- |
About Hubei Jumpcan Pharmaceutical Co Ltd
Hubei Jumpcan Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of medicines in China. The company offers drugs in the fields of pediatrics, respiratory system, digestive system, and gynecology. It is also involved in daily chemical product sales; and wholesale and retail pharmaceuticals. The company is headquartered in Taixing, China.